Y-mAbs Therapeutics Stock (NASDAQ:YMAB)
Previous Close
$10.86
52W Range
$5.29 - $20.90
50D Avg
$13.93
200D Avg
$13.80
Market Cap
$472.08M
Avg Vol (3M)
$262.49K
Beta
0.67
Div Yield
-
YMAB Company Profile
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
YMAB Performance
Peer Comparison
Ticker | Company |
---|---|
VECT | VectivBio Holding AG |
ZNTL | Zentalis Pharmaceuticals, Inc. |
RVMD | Revolution Medicines, Inc. Warrant |
MRUS | Merus N.V. |
LRMR | Larimar Therapeutics, Inc. |
DAWN | Day One Biopharmaceuticals, Inc. |
EWTX | Edgewise Therapeutics, Inc. |
ERAS | Erasca, Inc. |
BLUE | bluebird bio, Inc. |
TVTX | Travere Therapeutics, Inc. |
STRO | Sutro Biopharma, Inc. |
BDTX | Black Diamond Therapeutics, Inc. |
GBIO | Generation Bio Co. |
ARQT | Arcutis Biotherapeutics, Inc. |
BCEL | Atreca, Inc. |
SNDX | Syndax Pharmaceuticals, Inc. |
KRON | Kronos Bio, Inc. |
PASG | Passage Bio, Inc. |
CCCC | C4 Therapeutics, Inc. |
MRSN | Mersana Therapeutics, Inc. |
PCVX | Vaxcyte, Inc. |
MIRM | Mirum Pharmaceuticals, Inc. |